Patents by Inventor Vincent Mikol

Vincent Mikol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210189011
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: December 28, 2020
    Publication date: June 24, 2021
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Publication number: 20210047437
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: July 28, 2020
    Publication date: February 18, 2021
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • Publication number: 20200408765
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Patent number: 10759871
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 1, 2020
    Assignee: SANOFI
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Publication number: 20190119365
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 25, 2019
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 10112991
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20180155450
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Publication number: 20180100019
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: January 3, 2018
    Publication date: April 12, 2018
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20180030156
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Application
    Filed: July 10, 2017
    Publication date: February 1, 2018
    Inventors: Ercole RAO, Vincent MIKOL, Danxi LI, Jochen KRUIP, Matthew DAVISON
  • Publication number: 20170343550
    Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic rnyelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma.
    Type: Application
    Filed: January 9, 2017
    Publication date: November 30, 2017
    Inventors: Peter U. PARK, Laura M. BARTLE, Anna SKALETSKAYA, Viktor GOLDMAKHER, Daniel TAVARES, Jutta DECKERT, Vincent MIKOL, Veronique BLANC
  • Patent number: 9815902
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 14, 2017
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Patent number: 9738728
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 22, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 9732162
    Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 15, 2017
    Assignee: Sanofi
    Inventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
  • Patent number: 9676864
    Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: June 13, 2017
    Assignee: SANOFI
    Inventors: Herve Bouchard, Alain Commercon, Claudia Fromond, Vincent Mikol, Fabienne Parker, Ingrid Sassoon, Daniel Tavares
  • Publication number: 20170044263
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 16, 2017
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20160368977
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 22, 2016
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20160200811
    Abstract: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.
    Type: Application
    Filed: November 20, 2015
    Publication date: July 14, 2016
    Inventors: Nicolas Baurin, Christian Beil, Carsten Corvey, Christian Lange, Danxi Li, Vincent Mikol, Anke Steinmetz, Ercole Rao
  • Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9243067
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 26, 2016
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin